{"hands_on_practices": [{"introduction": "The journey from a genetic variant to a clinical outcome begins at the molecular level. This first practice uses a hypothetical in vitro experiment to illustrate how we can quantify the functional consequence of a transporter variant. By applying Michaelis-Menten kinetics, you will calculate the change in intrinsic uptake clearance ($CL_{\\text{int,uptake}}$), a fundamental parameter that reflects the transporter's efficiency and serves as a crucial input for larger pharmacokinetic models [@problem_id:4572250].", "problem": "A variant in Solute Carrier Organic Anion Transporter Family Member 1B1 (SLCO1B1), specifically the missense change valine to alanine at position $174$ (V174A; reference single nucleotide polymorphism identifier rs4149056), is known to alter hepatic uptake mediated by the encoded transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1). Consider in vitro uptake experiments conducted in transporter-expressing membrane preparations under conditions where uptake is well-described by saturable kinetics attributable to a single transporter system. Assume the uptake rate $v$ as a function of substrate concentration $[S]$ follows the Michaelis–Menten relationship, which is a well-tested description for carrier-mediated processes:\n$$\nv([S])=\\frac{V_{\\max}[S]}{K_{m}+[S]}.\n$$\nIn clinical pharmacology, the intrinsic uptake clearance, denoted $CL_{\\text{int,uptake}}$, is operationally defined as the initial slope of the uptake rate versus concentration relationship at low substrate concentrations (the linear, non-saturating limit), that is,\n$$\nCL_{\\text{int,uptake}}=\\lim_{[S]\\to 0}\\frac{v([S])}{[S]}.\n$$\nExperiments performed with wild-type SLCO1B1 and the V174A variant yield the following parameter estimates: wild-type $V_{\\max,\\text{WT}}=120$ pmol/min/mg protein and $K_{m,\\text{WT}}=8$ $\\mu$M; variant $V_{\\max,\\text{V174A}}=70$ pmol/min/mg protein and $K_{m,\\text{V174A}}=8$ $\\mu$M. Using only the definitions and relationships provided above, compute the fold-change in intrinsic uptake clearance for the V174A variant relative to wild-type, defined as\n$$\n\\text{fold-change}=\\frac{CL_{\\text{int,uptake,V174A}}}{CL_{\\text{int,uptake,WT}}}.\n$$\nRound your final answer to three significant figures and report it as a decimal number without units.", "solution": "The problem requires the calculation of the fold-change in intrinsic uptake clearance for the V174A variant of the OATP1B1 transporter relative to the wild-type (WT). The problem is valid as it is scientifically grounded, well-posed, and provides all necessary information.\n\nFirst, we must derive a formal expression for the intrinsic uptake clearance, $CL_{\\text{int,uptake}}$, from the provided definitions. The uptake rate $v$ as a function of substrate concentration $[S]$ is given by the Michaelis–Menten equation:\n$$\nv([S]) = \\frac{V_{\\max}[S]}{K_{m}+[S]}\n$$\nThe intrinsic uptake clearance is defined as the initial slope of the uptake rate versus concentration relationship at low substrate concentrations:\n$$\nCL_{\\text{int,uptake}} = \\lim_{[S]\\to 0}\\frac{v([S])}{[S]}\n$$\nTo find an expression for $CL_{\\text{int,uptake}}$ in terms of the Michaelis-Menten parameters $V_{\\max}$ and $K_m$, we substitute the expression for $v([S])$ into the definition of $CL_{\\text{int,uptake}}$:\n$$\nCL_{\\text{int,uptake}} = \\lim_{[S]\\to 0} \\left( \\frac{1}{[S]} \\cdot \\frac{V_{\\max}[S]}{K_{m}+[S]} \\right)\n$$\nFor $[S] \\neq 0$, the expression inside the limit can be simplified by canceling the $[S]$ terms in the numerator and denominator:\n$$\nCL_{\\text{int,uptake}} = \\lim_{[S]\\to 0} \\frac{V_{\\max}}{K_{m}+[S]}\n$$\nEvaluating the limit as $[S]$ approaches $0$ yields:\n$$\nCL_{\\text{int,uptake}} = \\frac{V_{\\max}}{K_{m}+0} = \\frac{V_{\\max}}{K_{m}}\n$$\nThis establishes that the intrinsic uptake clearance is the ratio of the maximum uptake rate to the Michaelis constant.\n\nNext, we apply this relationship to both the wild-type (WT) and the variant (V174A) transporters using the provided parameter values.\n\nFor the wild-type transporter:\n$V_{\\max,\\text{WT}} = 120$ pmol/min/mg protein\n$K_{m,\\text{WT}} = 8$ $\\mu$M\nThe intrinsic uptake clearance for the wild-type is:\n$$\nCL_{\\text{int,uptake,WT}} = \\frac{V_{\\max,\\text{WT}}}{K_{m,\\text{WT}}} = \\frac{120}{8} \\, \\frac{\\text{pmol/min/mg protein}}{\\mu\\text{M}}\n$$\n\nFor the V174A variant transporter:\n$V_{\\max,\\text{V174A}} = 70$ pmol/min/mg protein\n$K_{m,\\text{V174A}} = 8$ $\\mu$M\nThe intrinsic uptake clearance for the variant is:\n$$\nCL_{\\text{int,uptake,V174A}} = \\frac{V_{\\max,\\text{V174A}}}{K_{m,\\text{V174A}}} = \\frac{70}{8} \\, \\frac{\\text{pmol/min/mg protein}}{\\mu\\text{M}}\n$$\n\nThe problem asks for the fold-change, which is defined as the ratio of the variant's clearance to the wild-type's clearance:\n$$\n\\text{fold-change} = \\frac{CL_{\\text{int,uptake,V174A}}}{CL_{\\text{int,uptake,WT}}}\n$$\nSubstituting the expressions for the clearances:\n$$\n\\text{fold-change} = \\frac{\\left(\\frac{V_{\\max,\\text{V174A}}}{K_{m,\\text{V174A}}}\\right)}{\\left(\\frac{V_{\\max,\\text{WT}}}{K_{m,\\text{WT}}}\\right)} = \\frac{V_{\\max,\\text{V174A}}}{V_{\\max,\\text{WT}}} \\cdot \\frac{K_{m,\\text{WT}}}{K_{m,\\text{V174A}}}\n$$\nNow, we substitute the given numerical values into this expression:\n$$\n\\text{fold-change} = \\frac{70}{120} \\cdot \\frac{8}{8}\n$$\nThe $K_m$ values are identical, so their ratio is $1$:\n$$\n\\text{fold-change} = \\frac{70}{120} = \\frac{7}{12}\n$$\nTo obtain the final answer, we convert this fraction to a decimal and round to three significant figures as requested.\n$$\n\\frac{7}{12} \\approx 0.58333...\n$$\nRounding to three significant figures, we get $0.583$. This represents a reduction in intrinsic clearance for the variant to approximately $58.3\\%$ of the wild-type value.", "answer": "$$\\boxed{0.583}$$", "id": "4572250"}, {"introduction": "A change in a transporter's intrinsic function directly impacts how the body processes a drug. This exercise scales up from the molecular level to the whole-body level, using a one-compartment pharmacokinetic model to explore how a reduction in intrinsic clearance alters key systemic exposure metrics. You will derive and calculate the resulting changes in the area under the curve (AUC) and maximum plasma concentration ($C_{\\max}$), demonstrating the direct link between transporter genetics and drug exposure [@problem_id:4572230].", "problem": "A single-dose pharmacokinetic scenario is considered for simvastatin acid, an anionic drug whose hepatic uptake is mediated by Organic Anion Transporting Polypeptide 1B1 (OATP1B1), encoded by the solute carrier organic anion transporter family member 1B1 (SLCO1B1). Assume a one-compartment model with first-order oral absorption and linear elimination and a well-stirred liver. Hepatic clearance is the sole route of elimination. The hepatic extraction ratio is governed by the well-stirred model, hepatic availability is the complement of extraction, and oral bioavailability is the product of fraction absorbed, gut availability, and hepatic availability. The maximum concentration in plasma ($C_{\\max}$) arises from the solution of the one-compartment oral model, and the area under the plasma concentration-time curve (AUC) after an extravascular dose is proportional to the dose times bioavailability divided by systemic clearance.\n\nA low-function SLCO1B1 genotype reduces hepatic intrinsic clearance of uptake-mediated hepatic elimination. Let the baseline (normal-function) hepatic intrinsic clearance be $CL_{\\mathrm{int,norm}}$ and the low-function value be $CL_{\\mathrm{int,low}}=\\alpha\\,CL_{\\mathrm{int,norm}}$ with $\\alpha=0.20$. Assume the following parameter values (all other physiological and drug-specific characteristics remain unchanged between genotypes):\n- Hepatic blood flow $Q_{h}=90\\,\\mathrm{L\\,h^{-1}}$.\n- Unbound fraction in blood $f_{u}=0.05$.\n- Baseline hepatic intrinsic clearance $CL_{\\mathrm{int,norm}}=4000\\,\\mathrm{L\\,h^{-1}}$.\n- Fraction absorbed $F_{\\mathrm{abs}}=0.90$.\n- Gut availability $F_{g}=0.80$.\n- Apparent volume of distribution $V=150\\,\\mathrm{L}$.\n- First-order absorption rate constant $k_{a}=2.0\\,\\mathrm{h^{-1}}$.\n- Single oral dose $D=20\\,\\mathrm{mg}$.\n\nTasks:\n1) Starting from mass balance, the well-stirred liver model, and the one-compartment oral model, derive how a reduction in hepatic intrinsic clearance induced by low-function SLCO1B1 affects $C_{\\max}$ and AUC. Express $C_{\\max}$ in terms of $F$, $D$, $V$, $k_{a}$, and $k$, and express AUC in terms of $F$, $D$, and clearance. Then connect $F$ and clearance to $CL_{\\mathrm{int}}$ via the well-stirred model.\n2) Using the parameters above, compute the fold-change (low-function divided by normal-function) in $C_{\\max}$ and in AUC for the $20\\,\\mathrm{mg}$ dose. Report the final answer as a row matrix containing the two fold-changes in the order $C_{\\max}$-fold-change and AUC-fold-change. Round your answer to three significant figures. Express the final answer as dimensionless values (no units required).", "solution": "The problem is assessed to be valid as it is scientifically grounded in established pharmacokinetic principles, well-posed with sufficient and consistent data, and objectively formulated.\n\nThe solution proceeds in two parts as requested. The first part involves the derivation of the relationships between the key pharmacokinetic parameters and the hepatic intrinsic clearance. The second part involves the numerical computation of the fold-change in maximum plasma concentration ($C_{\\max}$) and area under the plasma concentration-time curve (AUC) due to the specified reduction in intrinsic clearance.\n\nPart 1: Derivations\n\nThe problem states that elimination is exclusively via hepatic clearance, so systemic clearance ($CL_{sys}$) is identical to hepatic clearance ($CL_h$). The well-stirred liver model defines $CL_h$ as a function of hepatic blood flow ($Q_h$), the unbound fraction of the drug in blood ($f_u$), and the hepatic intrinsic clearance ($CL_{\\mathrm{int}}$):\n$$CL_h = \\frac{Q_h \\cdot f_u \\cdot CL_{\\mathrm{int}}}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}$$\nThe hepatic extraction ratio ($E_h$) is the fraction of drug entering the liver that is eliminated during one pass, given by:\n$$E_h = \\frac{CL_h}{Q_h} = \\frac{f_u \\cdot CL_{\\mathrm{int}}}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}$$\nHepatic availability ($F_h$), the fraction of drug that passes through the liver without being eliminated, is the complement of the extraction ratio:\n$$F_h = 1 - E_h = 1 - \\frac{f_u \\cdot CL_{\\mathrm{int}}}{Q_h + f_u \\cdot CL_{\\mathrm{int}}} = \\frac{Q_h}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}$$\nThe total oral bioavailability ($F$) is the product of the fraction absorbed from the gut lumen ($F_{\\mathrm{abs}}$), the gut wall availability ($F_g$), and the hepatic availability ($F_h$):\n$$F = F_{\\mathrm{abs}} \\cdot F_g \\cdot F_h = F_{\\mathrm{abs}} \\cdot F_g \\cdot \\left(\\frac{Q_h}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}\\right)$$\nThis equation explicitly connects the oral bioavailability ($F$) to the intrinsic clearance ($CL_{\\mathrm{int}}$). A decrease in $CL_{\\mathrm{int}}$ leads to a decrease in the denominator, which increases $F_h$ and consequently increases $F$.\n\nThe area under the plasma concentration-time curve (AUC) after an oral dose ($D$) is given by:\n$$AUC = \\frac{F \\cdot D}{CL_{sys}} = \\frac{F \\cdot D}{CL_h}$$\nSubstituting the expressions for $F$ and $CL_h$:\n$$AUC = \\frac{\\left(F_{\\mathrm{abs}} \\cdot F_g \\cdot \\frac{Q_h}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}\\right) \\cdot D}{\\frac{Q_h \\cdot f_u \\cdot CL_{\\mathrm{int}}}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}} = \\frac{F_{\\mathrm{abs}} \\cdot F_g \\cdot D}{f_u \\cdot CL_{\\mathrm{int}}}$$\nThis derivation shows that AUC is inversely proportional to the product of the unbound fraction and the intrinsic clearance ($f_u \\cdot CL_{\\mathrm{int}}$). Since $f_u$ is constant, a reduction in $CL_{\\mathrm{int}}$ will lead to a proportional increase in AUC.\n\nFor a one-compartment model with first-order oral absorption, the plasma concentration ($C(t)$) at time $t$ is:\n$$C(t) = \\frac{F \\cdot D \\cdot k_a}{V \\cdot (k_a - k)} (\\exp(-k \\cdot t) - \\exp(-k_a \\cdot t))$$\nwhere $k_a$ is the absorption rate constant, $V$ is the apparent volume of distribution, and $k$ is the elimination rate constant. The elimination rate constant is related to clearance and volume of distribution:\n$$k = \\frac{CL_h}{V} = \\frac{1}{V} \\left(\\frac{Q_h \\cdot f_u \\cdot CL_{\\mathrm{int}}}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}\\right)$$\nThis shows that $k$ is also dependent on $CL_{\\mathrm{int}}$. A decrease in $CL_{\\mathrm{int}}$ will result in a decrease in $k$.\nThe time to maximum concentration ($t_{\\max}$) is found by setting the derivative $dC/dt$ to zero, which yields:\n$$t_{\\max} = \\frac{\\ln(k_a/k)}{k_a - k}$$\nThe maximum concentration ($C_{\\max}$) is the concentration at $t_{\\max}$:\n$$C_{\\max} = C(t_{\\max}) = \\frac{F \\cdot D}{V} \\exp(-k \\cdot t_{\\max})$$\nA reduction in $CL_{\\mathrm{int}}$ affects $C_{\\max}$ through two pathways:\n1. It increases bioavailability ($F$), which tends to increase $C_{\\max}$.\n2. It decreases the elimination rate constant ($k$), which prolongs $t_{\\max}$ and alters the exponential term $\\exp(-k \\cdot t_{\\max})$. The net effect on $C_{\\max}$ is a composite of these changes.\n\nPart 2: Numerical Computations\n\nThe given parameters are:\n$Q_{h}=90\\,\\mathrm{L\\,h^{-1}}$, $f_{u}=0.05$, $F_{\\mathrm{abs}}=0.90$, $F_{g}=0.80$, $V=150\\,\\mathrm{L}$, $k_{a}=2.0\\,\\mathrm{h^{-1}}$, $D=20\\,\\mathrm{mg}$, $CL_{\\mathrm{int,norm}}=4000\\,\\mathrm{L\\,h^{-1}}$, and $\\alpha=0.20$.\n\nThe low-function intrinsic clearance is $CL_{\\mathrm{int,low}}=\\alpha \\cdot CL_{\\mathrm{int,norm}} = 0.20 \\cdot 4000 = 800\\,\\mathrm{L\\,h^{-1}}$.\n\nWe first compute the parameters for the normal-function genotype (subscript 'norm'):\n$f_u \\cdot CL_{\\mathrm{int,norm}} = 0.05 \\cdot 4000 = 200\\,\\mathrm{L\\,h^{-1}}$.\n$CL_{h, \\mathrm{norm}} = \\frac{90 \\cdot 200}{90 + 200} = \\frac{18000}{290} = \\frac{1800}{29}\\,\\mathrm{L\\,h^{-1}}$.\n$k_{\\mathrm{norm}} = \\frac{CL_{h, \\mathrm{norm}}}{V} = \\frac{1800/29}{150} = \\frac{12}{29}\\,\\mathrm{h^{-1}}$.\n$F_{h, \\mathrm{norm}} = \\frac{90}{90 + 200} = \\frac{9}{29}$.\n$F_{\\mathrm{norm}} = 0.90 \\cdot 0.80 \\cdot \\frac{9}{29} = 0.72 \\cdot \\frac{9}{29} = \\frac{6.48}{29}$.\n\nNext, we compute the parameters for the low-function genotype (subscript 'low'):\n$f_u \\cdot CL_{\\mathrm{int,low}} = 0.05 \\cdot 800 = 40\\,\\mathrm{L\\,h^{-1}}$.\n$CL_{h, \\mathrm{low}} = \\frac{90 \\cdot 40}{90 + 40} = \\frac{3600}{130} = \\frac{360}{13}\\,\\mathrm{L\\,h^{-1}}$.\n$k_{\\mathrm{low}} = \\frac{CL_{h, \\mathrm{low}}}{V} = \\frac{360/13}{150} = \\frac{12}{65}\\,\\mathrm{h^{-1}}$.\n$F_{h, \\mathrm{low}} = \\frac{90}{90 + 40} = \\frac{9}{13}$.\n$F_{\\mathrm{low}} = 0.90 \\cdot 0.80 \\cdot \\frac{9}{13} = 0.72 \\cdot \\frac{9}{13} = \\frac{6.48}{13}$.\n\nFold-change in AUC:\nFrom the derivation, $AUC \\propto 1/CL_{\\mathrm{int}}$. Therefore, the fold-change is:\n$$\\frac{AUC_{\\mathrm{low}}}{AUC_{\\mathrm{norm}}} = \\frac{CL_{\\mathrm{int,norm}}}{CL_{\\mathrm{int,low}}} = \\frac{1}{\\alpha} = \\frac{1}{0.20} = 5$$\nTo three significant figures, this is $5.00$.\n\nFold-change in $C_{\\max}$:\nWe must compute $C_{\\max}$ for each genotype.\nFor the normal-function genotype:\n$k_a = 2.0\\,\\mathrm{h^{-1}}$, $k_{\\mathrm{norm}} = \\frac{12}{29}\\,\\mathrm{h^{-1}} \\approx 0.41379\\,\\mathrm{h^{-1}}$.\n$t_{\\max, \\mathrm{norm}} = \\frac{\\ln(k_a/k_{\\mathrm{norm}})}{k_a - k_{\\mathrm{norm}}} = \\frac{\\ln(2.0 / (12/29))}{2.0 - 12/29} = \\frac{\\ln(29/6)}{46/29}\\,\\mathrm{h} \\approx 0.99351\\,\\mathrm{h}$.\n$C_{\\max, \\mathrm{norm}} = \\frac{F_{\\mathrm{norm}} \\cdot D}{V} \\exp(-k_{\\mathrm{norm}} \\cdot t_{\\max, \\mathrm{norm}}) = \\frac{(6.48/29) \\cdot 20}{150} \\exp\\left(-\\frac{12}{29} \\cdot \\frac{\\ln(29/6)}{46/29}\\right)$.\n$C_{\\max, \\mathrm{norm}} = \\frac{4.46896...}{150} \\exp(-0.41110...) \\approx 0.029793 \\cdot 0.66293 \\approx 0.019751\\,\\mathrm{mg\\,L^{-1}}$.\n\nFor the low-function genotype:\n$k_a = 2.0\\,\\mathrm{h^{-1}}$, $k_{\\mathrm{low}} = \\frac{12}{65}\\,\\mathrm{h^{-1}} \\approx 0.18462\\,\\mathrm{h^{-1}}$.\n$t_{\\max, \\mathrm{low}} = \\frac{\\ln(k_a/k_{\\mathrm{low}})}{k_a - k_{\\mathrm{low}}} = \\frac{\\ln(2.0 / (12/65))}{2.0 - 12/65} = \\frac{\\ln(65/6)}{118/65}\\,\\mathrm{h} \\approx 1.31215\\,\\mathrm{h}$.\n$C_{\\max, \\mathrm{low}} = \\frac{F_{\\mathrm{low}} \\cdot D}{V} \\exp(-k_{\\mathrm{low}} \\cdot t_{\\max, \\mathrm{low}}) = \\frac{(6.48/13) \\cdot 20}{150} \\exp\\left(-\\frac{12}{65} \\cdot \\frac{\\ln(65/6)}{118/65}\\right)$.\n$C_{\\max, \\mathrm{low}} = \\frac{9.96923...}{150} \\exp(-0.24220...) \\approx 0.066462 \\cdot 0.78490 \\approx 0.052163\\,\\mathrm{mg\\,L^{-1}}$.\n\nThe fold-change in $C_{\\max}$ is the ratio:\n$$\\frac{C_{\\max, \\mathrm{low}}}{C_{\\max, \\mathrm{norm}}} = \\frac{0.052163}{0.019751} \\approx 2.6410$$\nRounding to three significant figures, the fold-change in $C_{\\max}$ is $2.64$.\n\nThe final answer is presented as a row matrix containing the fold-change in $C_{\\max}$ and the fold-change in AUC, in that order.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n2.64 & 5.00\n\\end{pmatrix}\n}\n$$", "id": "4572230"}, {"introduction": "The ultimate goal of pharmacogenomics is to improve patient safety and efficacy by informing clinical decisions. In this final practice, you will connect altered drug exposure to a real-world clinical outcome using data from a hypothetical population study. By calculating the odds ratio for statin-induced myopathy, you will quantify the clinical risk associated with a specific genotype and formulate an evidence-based recommendation, bridging the gap between quantitative analysis and patient care [@problem_id:4572238].", "problem": "A clinician is initiating simvastatin therapy for a hyperlipidemic adult with a documented Solute Carrier Organic Anion Transporter Family Member 1B1 (SLCO1B1) genotype corresponding to the haplotype $^{*}5/^{*}5$ (poor function), compared against an otherwise matched cohort with $^{*}1/^{*}1$ (normal function). Organic Anion Transporting Polypeptide 1B1 (OATP1B1), encoded by the SLCO1B1 gene, facilitates hepatic uptake of statins; decreased function alleles increase systemic exposure to the active acid form of simvastatin and are associated with an elevated risk of statin-associated myopathy. The planned dose is $20$ $\\mathrm{mg}$ simvastatin daily.\n\nConsider a population-based pharmacogenomic study at this dose in which, among $100{,}000$ $^{*}1/^{*}1$ individuals, $50$ experienced myopathy, and among $100{,}000$ $^{*}5/^{*}5$ individuals, $225$ experienced myopathy. Use the formal definition of the odds ratio for a binary outcome: if the probability of myopathy is $p$, then the odds are $p/(1-p)$, and the odds ratio is the ratio of odds between two groups. Compute the odds ratio of myopathy in $^{*}5/^{*}5$ versus $^{*}1/^{*}1$ at $20$ $\\mathrm{mg}$ simvastatin daily. Round your answer to three significant figures and express it as a unitless number.\n\nIn addition, based on the decreased function of OATP1B1 in the $^{*}5/^{*}5$ genotype and widely accepted clinical implementation principles (for example, those articulated by the Clinical Pharmacogenetics Implementation Consortium (CPIC)), propose an evidence-based dose reduction strategy or an alternative statin choice with a brief rationale. Your numerical answer should be only the computed odds ratio.", "solution": "The problem presents a valid and well-posed question grounded in established principles of clinical pharmacology and pharmacogenomics. It contains sufficient information to calculate the requested odds ratio and provide a clinical recommendation.\n\nThe problem requires the calculation of the odds ratio ($OR$) for myopathy in individuals with the *SLCO1B1* *5/*5 genotype compared to those with the *1/*1 genotype, when treated with simvastatin $20$ $\\mathrm{mg}$ daily.\n\nFirst, we define the two groups for comparison:\nGroup 1: Individuals with the *SLCO1B1* *1/*1 (normal function) genotype.\nGroup 2: Individuals with the *SLCO1B1* *5/*5 (poor function) genotype.\n\nFrom the data provided for a population-based study:\nFor Group 1 (*1/*1):\nNumber of individuals who experienced myopathy, $C_1 = 50$.\nTotal number of individuals, $N_1 = 100,000$.\nThe number of individuals who did not experience myopathy is $NC_1 = N_1 - C_1 = 100,000 - 50 = 99,950$.\n\nFor Group 2 (*5/*5):\nNumber of individuals who experienced myopathy, $C_2 = 225$.\nTotal number of individuals, $N_2 = 100,000$.\nThe number of individuals who did not experience myopathy is $NC_2 = N_2 - C_2 = 100,000 - 225 = 99,775$.\n\nThe problem states that the odds of an event are defined as $\\frac{p}{1-p}$, where $p$ is the probability of the event. For a given group, if $C$ is the number of cases (events) and $NC$ is the number of non-cases, the probability $p$ is $\\frac{C}{C+NC}$. The odds can be calculated directly from the counts as $\\frac{C}{NC}$.\n\nThe odds of myopathy for Group 1 ($\\text{Odds}_1$) is:\n$$\n\\text{Odds}_1 = \\frac{C_1}{NC_1} = \\frac{50}{99,950}\n$$\n\nThe odds of myopathy for Group 2 ($\\text{Odds}_2$) is:\n$$\n\\text{Odds}_2 = \\frac{C_2}{NC_2} = \\frac{225}{99,775}\n$$\n\nThe odds ratio ($OR$) is the ratio of the odds in Group 2 to the odds in Group 1:\n$$\nOR = \\frac{\\text{Odds}_2}{\\text{Odds}_1} = \\frac{\\left(\\frac{225}{99,775}\\right)}{\\left(\\frac{50}{99,950}\\right)}\n$$\n\nTo calculate the value, we rearrange the expression:\n$$\nOR = \\frac{225 \\times 99,950}{99,775 \\times 50}\n$$\n\nThis corresponds to the standard cross-product ratio from a $2 \\times 2$ contingency table, where the cells are $a$ (cases in exposed group), $b$ (non-cases in exposed group), $c$ (cases in unexposed group), and $d$ (non-cases in unexposed group). Here, Group 2 is the \"exposed\" group (to the genetic variant) and Group 1 is the \"unexposed\" group. Thus, $a=C_2=225$, $b=NC_2=99,775$, $c=C_1=50$, and $d=NC_1=99,950$. The formula is $OR = \\frac{ad}{bc}$.\n\nPerforming the calculation:\n$$\nOR = \\frac{22,488,750}{4,988,750} \\approx 4.508018\n$$\n\nThe problem requires rounding the answer to three significant figures.\n$$\nOR \\approx 4.51\n$$\n\nIn addition to the calculation, the problem asks for an evidence-based recommendation for the patient with the $^{*}5/^{*}5$ genotype.\nThe *SLCO1B1* gene encodes the hepatic uptake transporter OATP1B1. The $^{*}5/^{*}5$ genotype results in a poor-function phenotype of this transporter. Simvastatin acid is a substrate of OATP1B1. Decreased transporter function leads to reduced hepatic clearance and consequently increased systemic plasma concentrations of simvastatin acid. This increased systemic exposure is directly linked to an elevated risk of statin-associated myopathy, an observation confirmed by our calculated odds ratio of approximately $4.51$.\n\nBased on widely accepted clinical guidelines, such as those published by the Clinical Pharmacogenetics Implementation Consortium (CPIC), this patient is at a significantly increased risk for myopathy at the planned $20$ $\\mathrm{mg}$ daily dose of simvastatin. The evidence-based recommendation is not simply a dose reduction but a change of therapy. The CPIC guidelines for simvastatin and *SLCO1B1* poor function phenotype recommend using an alternative statin. Statins such as pravastatin and rosuvastatin are less dependent on OATP1B1 for their hepatic uptake compared to simvastatin. Fluvastatin is also a recommended alternative. Therefore, the most appropriate clinical action is to discontinue the plan for simvastatin and instead prescribe an alternative like pravastatin or rosuvastatin at an appropriate equipotent dose. This strategy mitigates the risk of myopathy by choosing a drug whose pharmacokinetics are not substantially altered by the patient's genetic variant. While lowering the simvastatin dose (e.g., to $10$ $\\mathrm{mg}$) is a theoretical option, it may not be sufficient to eliminate the excess risk and could compromise the therapeutic goal of lipid reduction. Thus, switching agents is the preferred, evidence-based strategy.", "answer": "$$\n\\boxed{4.51}\n$$", "id": "4572238"}]}